Neonatal diabetes and protein losing enteropathy: a case report

Citation metadata

Authors: Tamara McMillan, Rose Girgis and Elizabeth A. C. Sellers
Date: Apr. 21, 2016
From: BMC Medical Genetics(Vol. 17, Issue 1)
Publisher: BioMed Central Ltd.
Document Type: Report
Length: 1,825 words

Main content

Article Preview :

Author(s): Tamara McMillan1 , Rose Girgis2 and Elizabeth A. C. Sellers1


Neonatal diabetes is a monogenic form of diabetes with onset in the first 6 months of life. It occurs in 1 in 100,000 to 400,000 births [1]. Transient neonatal diabetes resolves within the first 18 months and predisposes to the development of diabetes later in life [2]. The most common underlying genetic causes of transient neonatal diabetes are due to imprinting defects of chromosome 6 [2]. Permanent neonatal diabetes is predominantly due to mutations in the KCNJ11 and ABCC8 genes which encode for subunits of the sulfonylurea receptor. Permanent neonatal diabetes can also be caused by mutations in the insulin gene or the GCK gene which encodes for the glucokinase enzyme [2].

Less commonly, neonatal diabetes results from pancreatic hypoplasia or agenesis. In a large study of 795 patients with neonatal diabetes, 39/795 (4.9 %) were found to have pancreatic agenesis (defined by the need for both insulin and having pancreatic exocrine insufficiency and need for enzyme replacement therapy)[3]. Mutations of PRX1 and PTF1A (found on chromosomes 13 and 10 respectively) are associated with pancreatic hypoplasia/agenesis. These genes encode for transcription factors required for pancreatic growth and development [4]. The GATA6 gene, on chromosome 18, has also been linked to neonatal diabetes and is the most common cause of pancreatic agenesis accounting for just over 50 % of cases [3]. This gene encodes for GATA6, a transcription factor involved in the development of multiple organ systems including the pancreas. Mutations of the GATA 6 gene may result in pancreatic hypoplasia or agenesis and are associated with other anomalies, most commonly congenital heart disease [5]. GATA6 mutations account for approx. 3 % of all cases of neonatal diabetes [3].

We report an infant presenting with neonatal diabetes resulting from a de novo heterozygous mutation in the GATA6 gene.

Submission of this report was approved by the Human Research Ethics Board, Faculty of Health Sciences, University of Manitoba.

Case presentation

A Caucasian male infant was born to a 33 year old G7P5SA2 mother and her non-consanguineous partner at 37 weeks gestation. The pregnancy was complicated by morning sickness treated with Diclectin[R] (doxylamine succinate/pyridoxine hydrochloride). There were no other exposures to known teratogens. Intrauterine growth restriction was noted on ultrasound at 20 weeks gestation (head circumference, weight, femur length all < 5%ile). Oligohydramnios was noted at 34 weeks gestation, and the mother was placed on bed rest.

Labour was induced at 37 weeks gestation for asymmetric growth restriction. The infant was delivered by caesarean section for failure to progress. Birth weight was 1580 grams (<3rd %ile), length was 40 centimeters (<3rd %ile) and head circumference was 31 centimeters (3rd-10th %ile). Apgar scores were 9 and...

Source Citation

Source Citation
McMillan, Tamara, et al. "Neonatal diabetes and protein losing enteropathy: a case report." BMC Medical Genetics, vol. 17, no. 1, 2016. Accessed 19 Jan. 2021.

Gale Document Number: GALE|A469984865